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The advantages of the mouse as a
model organism in biomedical research
are many. The molecular and genetic
toolbox developed for the mouse over the
last 100 years enables researchers to
manipulate and study gene function in
vivo almost at will. Time and time again,
scientific findings obtained through the use
of mouse models have proven to be
relevant to human health. The field of
immunology in particular has profited
tremendously from the powers of the
mouse model and much of our knowledge
of the workings of the immune system is
derived from studies performed in mice.
Yet all that glisters is not gold.
Researchers have used the mouse exten-
sively as a model organism to study the
pathogenesis of human infections and
found that it imperfectly recapitulates
many aspects of infectious disease as seen
in patients. In fact, mice generally appear
to be highly resistant to infections with
human-specific pathogens like HIV, Plas-
modium falciparum,a n dShigella flexneri,
especially if the pathogen is administered
through the natural route of infection. Of
course, the inherent resistance of mice to
highly adapted human pathogens should
not be a surprise: because pathogens co-
evolve with and adapt to their preferred
host, their successful specialization often
renders them highly dependent on their
host species [1]. Such host tropism or host
restriction limits the usefulness of the
mouse as a model for infectious disease
research. One approach to overcome the
limitations of the mouse model could be
to genetically engineer mice that closely
resemble humans in all those aspects
relevant for host–pathogen interactions.
To assess how realistic this ambitious goal
may be, we must first understand the




Contributes to Host Tropism
For many infectious diseases, host
restriction is at least in part based on the
inability of a pathogen to colonize the
non-typical host effectively. Colonization
often relies on species-specific interactions
of microbial ligands with host cell recep-
tors. For example, the bacterial effector
internalin A expressed by Listeria monocyto-
genes binds to the host E-cadherin receptor
to mediate bacterial internalization, an
essential step for the microbe to breach the
intestinal epithelial barrier after oral
ingestion [2]. A single amino acid change
in the mouse ortholog of E-cadherin
disrupts the interaction with internalin A
and abrogates efficient bacterial invasion
[2]. As a consequence, mice are relatively
resistant to L. monocytogenes infections
administered through the oral route.
Transgenic mice expressing human E-
caherin in the small intestine, on the other
hand, are susceptible to oral infections
with L. monocytogenes and develop enter-
opathogenicity and systemic infections,
thus truthfully recapitulating some aspects
of human disease [3].
Additionally, host restriction may be
caused by the failure of pathogens to deter
immune assaults in the non-typical host.
For bacterial pathogens, this principle has
been beautifully described for the human-
restricted pathogen Neisseria gonorrhoeae, the
causative agent of gonorrhea. Outer
membrane porin molecules of N. gonor-
rhoeae can bind human but not rodent
inhibitory molecules of the alternative and
classical complement pathways, rendering
gonococci resistant to complement-medi-
ated killing by human serum but suscep-
tible to rodent serum [4,5]. In contrast,
Yersinia pestis, a pathogen of both humans
and rodents, binds complement inhibitory
molecules of either host species and evades
both human and rodent serum-mediated
killing [4]. This example illustrates a
general principle: a pathogen must be able
to endure or overcome innate immune
responses that drastically interfere with its
survival and/or transmission to another
suitable host. Pathogens must, therefore,
have evolved subversion strategies for all
the innate immune mechanisms that, if
unrestricted, would result in their demise.
A pathogen will, of course, acquire
immune evasion strategies only against
antimicrobial responses active in the host
species with which it has co-evolved.
Highly adapted human pathogens would
therefore be vulnerable to an antimicrobi-
al immune pathway present in mice but
absent from humans. Recent work on
IFNc-activated host responses to intracel-
lular pathogens has indentified a powerful
cell-autonomous host defense system or-
chestrated by a family of GTPases named
p47 Immunity Related GTPase (IRG
proteins) that is present in mice but
appears to be largely absent from humans
and may exert limited antimicrobial func-
tions in humans compared to mice
[6,7,8,9].




Activation of the mammalian innate
immune system by the cytokine IFNc is
essential for host resistance to many
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produced by specialized immune cells, its
receptors are found on nearly all cells,
where it activates diverse responses that
enable host cells to ward off intracellular
infections by bacterial, viral, and protozo-
an pathogens [10,11]. A few of the
responses and their mediators are now
well characterized, in particular the pro-
duction of nitric oxide, the production of
oxygen radicals, and the depletion of
intracellular tryptophan stores by, respec-
tively, inducible nitric oxide synthase,
phagocyte oxidase, and indoleamine 2,3-
dioxygenase (IDO) [10,11]. However, it
has been long known that these mecha-
nisms cannot account for all the effects of
the IFNc response that result in cell-
autonomous resistance to intracellular
pathogens. Recently, this void in our
knowledge has been partly filled with the
discovery that several members of the IRG
gene family exercise highly effective anti-
microbial activities directed at a diverse set
of bacterial and protozoan pathogens.
Several research groups have used a gene
knockout approach in mice to study the
function of select representatives of the
IRG family in host resistance. So far, mice
lacking Irgm1/Lrg-47, Irgm3/Igtp, Irgd/Irg-47,
and Irga6/Iigp1 have been reported and
shown to display some dramatic susceptibil-
ity phenotypes to several pathogens, high-
lighting the essential role of the murine IRG
system in resistance to many infectious
agents [12,13,14].
Stark Differences Exist between
the Murine and Human IRG
Resistance Systems
In light of the importance of IRG-
mediated immunity in mice, it was sur-
prising to find that an IFNc-inducible IRG
system appears to be lacking in humans. In
contrast to mice, which express as many as
18 separate IRG genes upon IFNc stim-
ulation, the human genome possess only
two IRG genes, IRGC and IRGM, neither
of which is IFN-inducible [6]. The re-
stricted expression pattern of IRGC,
detected only in male gonads in both mice
and humans, suggests that it does not play
a universal role in the innate immune
response [6]. IRGM, on the other hand, is
constitutively expressed in a number of
human cell lines. However, the severe
truncations of IRGM protein compared to
mouse IRG proteins suggests that the
human IRGM must be functionally distinct
from its mouse orthologs [6]. Therefore, it
was surprising that both human IRGM and
mouse Irgm1 were reported to play a role
in the induction of autophagy, a multi-
purpose cellular process with antimicrobial
activity [15,16,17]. Notwithstanding some
potential overlap in function, mouse IRGs
but not human IRGM have been implicat-
ed in several additional antimicrobial
activities other than autophagy, namely
accelerated maturation of phagosomes,
disintegration of pathogen-containing vac-
uoles through vesiculation of vacuolar
membranes, and the modification of lipid
trafficking (Figure 1) [13,18,19,20].
Though a more careful analysis of the
molecular activities of human IRGM will
be required to draw any definitive conclu-
sions, it seems as if the human IRG system
has been stripped of most effector functions
found in mice, with the exception of a
regulatory role in autophagy. Whether any
of these additional IRG-driven antimicro-
bial activities that exist in mice are lacking
in human cells is currently not known. It
mayverywell bethat the immunefunctions
embodied by IRGs in mice have been
preserved in humans but are executed by a
different set of molecules, a principle that is
exemplified by the convergent evolution of
Figure 1. The Mouse and Human IRG Resistance Systems Are Distinct. In mouse cells as many as 18 IRGs are being induced upon IFNc
stimulation and mediate several antimicrobial activities, including the vesiculation of pathogen-containing vacuoles and accelerated maturation of
phagosomes. Overexpression of mouse Irgm1 has also been shown to induce autophagy in macrophage-like RAW 264.7 cells [15], but so far no
defect in autophagy in Irgm1 knockout macrophages has been reported. IFNc is likely to induce autophagy also in an IRG-independent manner. In
contrast to mouse IRGs, human IRGM is not IFNc-inducible. IRGM has been shown to play a regulatory role in the execution of antimicrobial
autophagy, but has not been associated with additional antimicrobial activities.
doi:10.1371/journal.ppat.1000333.g001
PLoS Pathogens | www.plospathogens.org 2 May 2009 | Volume 5 | Issue 5 | e1000333NK inhibitory receptors in mice and
humans [21]. In this context, it is worth
mentioning that some of the most strongly
induced proteins in IFNc-activated cells
belong to another GTPase family, the p65
guanylate binding proteins (GBPs), which
are highly conserved between mice and
humans [22]. Remarkably, it has recently
been shown that GBPs like IRGs localize to
the parasitophorous vacuolar membrane
surrounding the protozoal pathogen Toxo-
plasma gondii [23]. Although the importance
of this observation is presently unclear, it is
suggestive of GBPs exerting immune effec-
tor functions that may be related to the






Human Cells but IRG Responses
in Mouse Cells
Strong support for the hypothesis that
human IRGM exerts limited antimicrobial
responses compared to the murine IRG
system came from studies of the host
response to the human intracellular bac-
terial pathogen C. trachomatis. In human
cells, IFNc-activated resistance to C.
trachomatis depends predominantly on
IDO-mediated tryptophan depletion
[24,25]. Supplementing growth media
with tryptophan, thus specifically neutral-
izing the effect of IDO, completely
reverses the growth inhibitory effect of
IFNc on C. trachomatis in most human cell
lines in spite of detectable IRGM expres-
sion [6,24]. Based on the assumption that
IDO and IRGM act in distinct pathways,
these results strongly suggest that IRGM
does not exert IFNc-dependent antimicro-
bial effects towards C. trachomatis in human
cells. However, direct functional studies
are required to decisively determine the
role of IRGM in resistance to C. trachomatis
infections in human cells. In contrast to
human cells, most mouse cells do not
induce IDO expression upon IFNc stim-
ulation [24,26,27], and IDO-deficient
mice display wild-type resistance to C.
trachomatis infections [20]. Instead, mice
require at least three IRG genes, Irgb10,
Irgm1, and Irgm3, for resistance to C.
trachomatis infections both in vivo and in
IFNc-stimulated cells in vitro [28,29].
Collectively, these studies show that the
IRG system is essential for the innate
immune response to C. trachomatis in mice,
whereas IRGM appears to play no role in
IFNc-induced cell-autonomous resistance
to C. trachomatis infections in many, if not
all, human cells.
Host-Adapted Chlamydia Strains
Evade the IFNc Response
Specific to Their Respective
Hosts
Because of the disparate effector func-
tions of the human and mouse IFNc
response, it is expected that host-adapted
pathogens for these two species should be
equally divergent in their immune evasion
strategies. In support of this hypothesis, we
were recently able to show that the mouse-
adapted strain Chlamydia muridarum, but not
its close relative C. trachomatis, can specif-
ically evade IRG-mediated host resistance
by blocking access of IRG proteins to the
Chlamydia-surrounding vacuolar mem-
brane, the inclusion membrane [29]. On
the other hand, and complementary to
these results, C. trachomatis strains isolated
from the human urogenital tract, but not
C. muridarum, express tryptophan synthase,
an enzyme capable of using exogenous
indole for the synthesis of tryptophan
[30,31]. The ability of C. trachomatis to
use indole (probably generated by the local
microbial flora of the genital tract) pro-
vides C. trachomatis with a lifeline to endure
IDO-mediated tryptophan starvation, and
this is potentially a key element in the
establishment of persistent infections in
humans [30]. The divergent counterim-
mune mechanisms employed by the hu-
man pathogen C. trachomatis and the
mouse-adapted pathogen C. muridarum
clearly reflect the differences in the IFNc
responses of their respective hosts, a
paradigm we expect to see recapitulated
in other host–pathogen interactions.
Do Other Mouse-Adapted
Pathogens Counteract the IRG
Response?
IRG genes are found throughout the
vertebrate subphylum, but their represen-
tation is erratic: for instance, the genomes
of zebrafish, rats, and dogs harbor IRGs,
whereas the chicken genome is so far
devoid of IRG genes [6]. We postulate
here that pathogens adapted to IRG-
deficient hosts (e.g., humans) are highly
vulnerable to the antimicrobial effects of
IRGs because these pathogens have not
been under evolutionary pressure to ac-
quire immune evasion strategies targeting
IRG responses. Accordingly, the recent
observation that the zoonotic pathogen
Chlamydia psittaci is highly susceptible to
IRG responses in mice [32] makes perfect
sense given that birds, the natural host of
C. psittaci, probably lack IRG genes [6].
Additionally, we postulate that intracellu-
lar vacuolar pathogens adapted to IRG-
expressing hosts (e.g., mice) have evolved
mechanisms to resist the IRG responses of
their hosts, as demonstrated for C. mur-
idarum. At a first glance this proposition
seems to be in conflict with published work
on T. gondii, a natural protozoal pathogen
of mice, which has been shown to be
susceptible to the IRG resistance system
[12,13,14,18]. However, in all of these
studies a naturally occurring avirulent type
II strain of T. gondii was used, while it has
been recently shown that a virulent type I
strain possesses an anti-IRG evasion
strategy [33,34]. Why does such an
avirulent T. gondii strain exist? It seems
likely on general grounds that IRG
immune evasion by virulent Toxoplasma
strains could decrease fitness of the
pathogen because the IRG resistance
system rescues the mouse from early
mortality but does not prevent avirulent
strains from establishing a chronic infec-
tion. In contrast, type I strains cause early
death in mice in spite of a functional IRG
system, thus reducing the likelihood of
successful transmission of Toxoplasma to a
new host. Since Toxoplasma is also a
remarkably promiscuous pathogen, infect-
ing many different intermediate hosts that
are prey to cats, it should also be
considered that not all its polymorphic
variants are necessarily adaptations to
successful colonization of mice. Neverthe-
less, it is clear that the IRG resistance
mechanism is an important part of the co-
adaptation between mice and Toxoplasma.
In contrast, IRG-mediated effects play no
part in human resistance to Toxoplasma,
while resistance via tryptophan depletion
caused by IFN-induced IDO has been well
documented (reviewed in [35]). Indeed,
the striking virulence difference between
T. gondii type I strains on the one hand and
types II and III strains on the other has
been documented only in mice; in humans
the clinical differences are subtle [36]. So
far, T. gondii and C. muridarum are the only
mouse-adapted pathogens that have been
analyzed to some degree in relation to the
IRG resistance mechanism. However, we
expect that other rodent-adapted patho-
gens like Y. pestis or Plasmodium berghei,
which have not been analyzed in this
context, will also feature IRG evasion
mechanisms. It would be of great interest
to establish whether in general the pres-
ence of an efficient IRG resistance system
in a species predicts a reduced IDO
resistance system and vice versa. So far
we have only humans and mice as the
polar cases.
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Models to Study Human
Infectious Disease
The host specificity of a pathogen arises
from continued selection over thousands
or millions of years for adaptation to the
ecological niche provided by the host
species. When a pathogen is introduced
into a non-typical host (i.e., a host the
pathogen has not co-evolved with), the
acquired molecular fine-tuning is lacking.
Consequently, the outcome of an encoun-
ter between a pathogen and a non-typical
host differs in several aspects from the
characteristics of an infection of a typical
or natural host. Many combinations of
host species with co-evolved pathogens
lead to chronic infections with low path-
ogen load and inefficient establishment of
immunity. In contrast, experimental infec-
tions of non-typical hosts often result in
acute pathogenicity to the host, followed
by complete clearance of the infection and
rapid development of effective immunity
after a single exposure [37]. Given the
striking differences between human infec-
tions and the phenotypes displayed by
mice exposed to the same human-adapted
pathogens, it often becomes problematic
to translate knowledge obtained in mouse
studies to human diseases. Better animal
models may provide a solution to this
conundrum. Because chimpanzees are
evolutionarily more closely related to
humans, they are susceptible to many
human pathogens and often display symp-
toms similar to those seen during infection
of humans. Nonetheless, genetic differenc-
es still exist between humans and chim-
panzees that affect host–pathogen interac-
tions [4,38,39,40,41]. More importantly,
there are ethical considerations as well as
practical disadvantages inherent in pri-
mate models (e.g., high costs), which argue
against the widespread use of these animal
models in infectious disease research.
Mouse models that more closely resemble
human disease could serve as an alterna-
tive, though the establishment of such
models will be difficult. Indeed, the
construction of a Mus homunculus for
research in immunobiology may appear
to be a Sysiphean task: each barrier
broken will reveal the next. Moreover,
for every pathogen a different set of
obstacles will have to be tackled. However,
it may not be necessary to mimic faithfully
every aspect of the human system in a
mouse model as long as some features
have been humanized that are relevant to
the scientific question being asked. For
instance, replacing the IRG-mediated
resistance system with the IDO-mediated
resistance system in urogenital epithelial
cells using a gene-targeted mouse model
should enable us to study the role of IFNc-
induced tryptophan depletion in the
establishment of persistent C. trachomatis
genital infections. Though the creation of
humanized mouse models for infectious
disease will require substantial effort and
resources, the long-term benefits of these
new models would undoubtedly be enor-
mous.
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